430 related articles for article (PubMed ID: 15217321)
21. Dapsone drug resistance in the MDT era.
Roche PW; Neupane KD; Failbus SS; Butlin CR
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
[No Abstract] [Full Text] [Related]
22. [Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver tolerance of multibacillary patients. Therapeutic consequences].
Millan J; Roux G; Loko S; Naudin JC; Boucher P; Bodian M; Camara M; Moreira-Diop T; Grosset J
Acta Leprol; 1986; 4(4):427-44. PubMed ID: 3296613
[TBL] [Abstract][Full Text] [Related]
23. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
24. Relapses after a single dose of rifampin in skin-smear negative multibacillary patients after dapsone monotherapy.
Jamet P; Blanc L; Fayne OC; Traore I; Bobin P
Int J Lepr Other Mycobact Dis; 1994 Jun; 62(2):209-14. PubMed ID: 8046259
[TBL] [Abstract][Full Text] [Related]
25. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Sampaio EP; Malta AM; Sarno EN; Kaplan G
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
[TBL] [Abstract][Full Text] [Related]
26. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy.
Shetty VP; Wakade AV; Ghate S; Pai VV; Ganapati R; Antia NH
Int J Lepr Other Mycobact Dis; 2003 Sep; 71(3):210-7. PubMed ID: 14608816
[TBL] [Abstract][Full Text] [Related]
27. Results of a modified WHO regimen in highly bacilliferous BL/LL patients.
Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa ; Sharma VD; Shivannavar CT; Katoch VM
Int J Lepr Other Mycobact Dis; 1989 Jun; 57(2):451-7. PubMed ID: 2664042
[TBL] [Abstract][Full Text] [Related]
28. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
[TBL] [Abstract][Full Text] [Related]
30. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
31. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT.
Katoch K; Natarajan M; Bagga A; Katoch VM
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):248-54. PubMed ID: 2071982
[TBL] [Abstract][Full Text] [Related]
32. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
Pönnighaus JM; Boerrigter G
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
[TBL] [Abstract][Full Text] [Related]
33. Viability of Mycobacterium leprae in lepromatous patients after five years of dapsone monotherapy supplemented with two years of multidrug therapy.
Sivaprasad N; Snehalatha S; Lobo D; Aschhoff M; Job CK
Indian J Lepr; 1995; 67(4):427-33. PubMed ID: 8849919
[TBL] [Abstract][Full Text] [Related]
34. Drug resistance in leprosy: lessons from past and future perspective.
Gupta UD; Katoch VM
Indian J Lepr; 1999; 71(4):451-63. PubMed ID: 10804973
[TBL] [Abstract][Full Text] [Related]
35. A case of relapse with drug-susceptible M. leprae after multidrug therapy.
Constant-Desportes M; Guelpa-Lauras CC; Carolina JC; Léoture A; Grosset JH; Sansarricq H
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):242-7. PubMed ID: 2071981
[TBL] [Abstract][Full Text] [Related]
36. Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, the Philippines, and Korea.
Cellona RV; Fajardo TT; Kim DI; Hah YM; Ramasoota T; Sampattavanich S; Carrillo MP; Abalos RM; dela Cruz EC; Ito T
Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):1-11. PubMed ID: 2181040
[TBL] [Abstract][Full Text] [Related]
37. Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients: a five-year report.
Thomas A; Balakrishnan A; Nagarajan M; Prabhakar R; Tripathy SP; Christian M; Somasundaram PR
Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):273-80. PubMed ID: 2198314
[TBL] [Abstract][Full Text] [Related]
38. Relapse study in smear positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu, Philippines.
Maghanoy A; Mallari I; Balagon M; Saunderson P
Lepr Rev; 2011 Mar; 82(1):65-9. PubMed ID: 21644473
[TBL] [Abstract][Full Text] [Related]
39. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines.
Balagon MF; Cellona RV; Cruz Ed; Burgos JA; Abalos RM; Walsh GP; Saunderson PR; Walsh DS
Am J Trop Med Hyg; 2009 Nov; 81(5):895-9. PubMed ID: 19861628
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of a four-week, ofloxacin-containing regimen compared with standard WHO-MDT in PB leprosy.
Balagon MF; Cellona RV; Abalos RM; Gelber RH; Saunderson PR
Lepr Rev; 2010 Mar; 81(1):27-33. PubMed ID: 20496567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
